Trial Profile
A Randomised, Open-Label, Single-Dose, Parallel Group Study to Assess the Comparative Oral Bioavailability of Two Capsule Formulations of MT-1303 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Amiselimod (Primary)
- Indications Crohn's disease; Multiple sclerosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 16 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Dec 2014 New trial record